WeVote
Log In

Bill

Bill

HB 195

Relating to designating certain substances as Schedule IV controlled substances under the Texas Controlled Substances Act.

89th Legislature, 2nd Called Session (2025) Introduced by Pat Curry

HB 195 would reclassify certain unspecified substances as Schedule IV controlled drugs in Texas, affecting law enforcement, medical access, and sentencing standards.

Referred to State Affairs
#abortion(i0005) #crimes--drugs(i0185) #health--general(i0385) #medicine&prescriptiondrugs(s7338) #texascontrolledsubstancesact(p0009) #women(i0925)
0
WeVote Research Nonpartisan
Bill Summary · HB 195

Legislative bill overview

HB 195 proposes to reclassify certain substances as Schedule IV controlled substances under Texas's Controlled Substances Act. The bill was filed in August 2025 and has been referred to the State Affairs Committee for consideration. The specific substances targeted for reclassification are not detailed in the provided information.

Why is this important

Schedule IV classification represents a moderate level of regulatory control, typically applied to substances with accepted medical uses but potential for abuse. How Texas categorizes drugs affects law enforcement priorities, sentencing guidelines, medical accessibility, and pharmaceutical regulation within the state. Changes to scheduling can have significant implications for healthcare providers, patients needing legitimate medications, and criminal justice outcomes.

Potential points of contention

  • Lack of specification: Without knowing which substances are targeted, it's unclear whether this addresses emerging drugs, pharmaceutical reclassification, or other compounds—making it difficult to assess public health justification
  • Medical vs. enforcement balance: Schedule IV placement must balance preventing drug abuse against ensuring physicians and patients can access legitimate treatments; stakeholders may disagree on where specific substances belong
  • Federal-state coordination: Texas scheduling must align with or justify deviations from federal DEA classifications; misalignment can create legal and practical complications

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.